Micro RNA-148a Targets Bcl-2 in Patients with Non-Small Cell Lung Cancer

Asian Pac J Cancer Prev. 2021 Jun 1;22(6):1949-1955. doi: 10.31557/APJCP.2021.22.6.1949.

Abstract

Objective: Lung cancer is one of the most prevalent cancers and the leading cause of cancer-related deaths worldwide. MicroRNAs regulate more than 60% of human genes, including tumor suppressor genes and oncogenes. Accordingly, they can affect cancer risk. This study aimed to evaluate the role of serum miR-148a as a non-invasive biomarker in non-small cell lung cancer (NSCLC) patients and to assess the correlation between miR-148a and Bcl-2, as one of its target proteins.

Materials and methods: A total of 50 newly diagnosed NSCLC cases and 30 apparently healthy controls were recruited in this study. MiR-148a level was measured by TaqMan- Real time RT-PCR assay and Bcl-2 level was measured by ELISA.

Results: Significant lower expression of serum miR-148a and higher serum Bcl-2 levels were observed in NSCLC patients as compared to the control group (p.

Keywords: Bcl-2; MiR-148a; NSCLC.

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / blood
  • Carcinoma, Non-Small-Cell Lung / blood*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Case-Control Studies
  • Egypt
  • Female
  • Humans
  • Lung Neoplasms / blood*
  • Male
  • MicroRNAs / blood*
  • Neoplasm Grading
  • Neoplasm Staging
  • Proto-Oncogene Proteins c-bcl-2 / blood*

Substances

  • BCL2 protein, human
  • Biomarkers, Tumor
  • MicroRNAs
  • Proto-Oncogene Proteins c-bcl-2